Half-Life of Serum Elimination of Perfluorooctanesulfonate,Perfluorohexanesulfonate, and Perfluorooctanoate in Retired Fluorochemical Production Workers
Top Cited Papers
- 1 September 2007
- journal article
- research article
- Published by Environmental Health Perspectives in Environmental Health Perspectives
- Vol. 115 (9) , 1298-1305
- https://doi.org/10.1289/ehp.10009
Abstract
The presence of perfluorooctanesulfonate (PFOS), perfluorohexanesulfonate (PFHS), and perfluorooctanoate (PFOA) has been reported in humans and wildlife. Pharmacokinetic differences have been observed in laboratory animals. The purpose of this observational study was to estimate the elimination half-life of PFOS, PFHS, and PFOA from human serum. Twenty-six (24 male, 2 female) retired fluorochemical production workers, with no additional occupational exposure, had periodic blood samples collected over 5 years, with serum stored in plastic vials at -80 degrees C. At the end of the study, we used HPLC-mass spectrometry to analyze the samples, with quantification based on the ion ratios for PFOS and PFHS and the internal standard (18)O(2)-PFOS. For PFOA, quantitation was based on the internal standard (13)C(2)-PFOA. THE ARITHMETIC MEAN INITIAL SERUM CONCENTRATIONS WERE AS FOLLOWS: PFOS, 799 ng/mL (range, 145-3,490); PFHS, 290 ng/mL (range, 16-1,295); and PFOA, 691 ng/mL (range, 72-5,100). For each of the 26 subjects, the elimination appeared linear on a semi-log plot of concentration versus time; therefore, we used a first-order model for estimation. The arithmetic and geometric mean half-lives of serum elimination, respectively, were 5.4 years [95% confidence interval (CI), 3.9-6.9] and 4.8 years (95% CI, 4.0-5.8) for PFOS; 8.5 years (95% CI, 6.4-10.6) and 7.3 years (95% CI, 5.8-9.2) for PFHS; and 3.8 years (95% CI, 3.1-4.4) and 3.5 years (95% CI, 3.0-4.1) for PFOA. Based on these data, humans appear to have a long half-life of serum elimination of PFOS, PFHS, and PFOA. Differences in species-specific pharmacokinetics may be due, in part, to a saturable renal resorption process.Keywords
This publication has 20 references indexed in Scilit:
- The Applicability of Biomonitoring Data for Perfluorooctanesulfonate to the Environmental Public Health ContinuumEnvironmental Health Perspectives, 2006
- Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys—Probing the determinants of long plasma half-livesToxicology, 2006
- Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO)Toxicology, 2006
- Pharmacokinetics of Perfluorooctanoate in Cynomolgus MonkeysToxicological Sciences, 2004
- Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibitionAmerican Journal of Physiology-Renal Physiology, 2004
- The Molecular Pharmacology of Organic Anion Transporters: from DNA to FDA?Molecular Pharmacology, 2004
- Binding of Perfluorooctanoic Acid to Rat Liver‐form and Kidney‐form α2u‐GlobulinsDrug and Chemical Toxicology, 2004
- TOXICITY AND TOXICOKINETICS OF PERFLUOROOCTANOIC ACID IN HUMANS AND ANIMALSThe Journal of Toxicological Sciences, 2003
- Lack of evidence for perfluorodecanoyl- or perfluorooctanoyl-coenzyme a formation in male and female ratsJournal of Biochemical Toxicology, 1992
- Tissue distribution, metabolism, and elimination of perfluorooctanoic acid in male and female ratsJournal of Biochemical Toxicology, 1991